|
| Press Releases |
|
 |
|
| Tuesday, March 15, 2022 |
|
|
Biogen and Eisai Amend Collaboration Agreements on Alzheimer's Disease Treatments |
| Biogen Inc. and Eisai Co., Ltd. announced today that the companies have amended their existing collaboration agreement on aducanumab, which is commercialized in the United States as ADUHELM (aducanumab-avwa). more info >> |
|
| Friday, March 11, 2022 |
|
|
Eisai to Present New Lecanemab Data Exploring Distinct Mechanism of Action and Clinical Outcomes, Disease State (DSE) Symposium, and Other Pipeline Assets at the AD/PD 2022 Annual Meeting |
| Eisai Co., Ltd. announced today the company will present research from its robust Alzheimer's disease (AD) pipeline, including the latest findings on lecanemab, Eisai's investigational anti-amyloid beta (Abeta) protofibril antibody for the treatment of early AD at the AD/PD 2022 International Conference on Alzheimer's and Parkinson's Diseases (AD/PD) from March 15-20 in Barcelona, Spain and virtually. more info >> |
|
| Wednesday, March 9, 2022 |
|
|
Eisai Certified as the 2022 Health and Productivity Management Outstanding Organization (White 500) |
| Eisai Co., Ltd. announced today that it has been certified as the Health and Productivity Management Outstanding Organization in the large enterprise category (White 500) by Japan's Ministry of Economy, Trade and Industry and the Nippon Kenko Kaigi. more info >> |
|
| Monday, March 7, 2022 |
|
|
LENVIMA in Combination with KEYTRUDA Approved In Taiwan for the Treatment of Patients with Advanced Endometrial Carcinoma |
| Eisai Co., Ltd. announced today that LENVIMA (generic name: lenvatinib mesylate), the multiple receptor tyrosine kinase inhibitor discovered by Eisai, in combination with Merck & Co., Inc., Kenilworth, N.J., U.S.A. more info >> |
|
| Friday, March 4, 2022 |
|
|
Eisai Initiates Submission of Application Data Under the Prior Assessment Consultation System in Japan with the Aim of Obtaining Early Approval for Investigational Anti-Amyloid Beta Protofibril Antibody Lecanemab |
| Eisai Co., Ltd. and Biogen Inc. announced today that Eisai has initiated a submission to the Pharmaceuticals and Medical Devices Agency (PMDA) of application data under the prior assessment consultation system in Japan for the investigational anti-amyloid beta (Abeta) protofibril antibody lecanemab (BAN2401). more info >> |
|
| Friday, February 25, 2022 |
|
|
Eisai: LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Approved in Japan for Radically Unresectable or Metastatic Renal Cell Carcinoma |
| Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. (known as MSD outside the United States and Canada) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved the combination of LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, plus KEYTRUDA. more info >> |
|
| Tuesday, February 1, 2022 |
|
|
Eisai Receives the Tokyo Governor Prize for Corporate Governance of the Year 2021 |
| Eisai Co., Ltd. announced today that it was selected as the winner of the Tokyo Governor Prize for Corporate Governance of the Year 2021, which is an award program organized by the Japan Association of Corporate Directors (JACD). more info >> |
|
| Monday, January 31, 2022 |
|
|
Eisai: Lenvima (Lenvatinib) in Combination with Keytruda (Pembrolizumab) Approved in Taiwan for the First-Line Treatment of Patients with Advanced Renal Cell Carcinoma |
| This marks the first approval for LENVIMA which will be used in combination with KEYTRUDA for advanced RCC in Asia. more info >> |
|
| Friday, January 28, 2022 |
|
|
Eisai Announces Results and Continued Support of Initiatives for Elimination of Neglected Tropical Diseases |
| Eisai Co., Ltd. announced today that its CEO Haruo Naito participated in the online event entitled "100% COMMITTED to End NTDs" celebrating the 10th anniversary of the London Declaration, an international public-private partnership to eliminate neglected tropical diseases (NTDs), on January 27, 2022. more info >> |
|
|
Eisai: Update on the Phase 4 ENVISION Confirmatory Study of ADUHELM |
| Biogen Inc. and Eisai Co., Ltd. (Tokyo, Japan) today announced additional details about the Phase 4 post-marketing confirmatory study, ENVISION, of ADUHELM (aducanumab-avwa) 100 mg/mL injection for intravenous use in early Alzheimer's disease, including details of the study's goal for diverse enrollment and primary endpoint. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
OBI Pharma and TegMine Therapeutics Sign Exclusive Global License Agreement for Glycan-Targeting ADC
Jan 12, 2026 20:00 HKT/SGT
|
|
|
Charlie's Holdings (OTCQB:CHUC) Signs Agreement with IKE Tech to Commercialize Transformational Age-Gated Vapes that Will Address FDA Concerns Related to Youth Access
Jan 12, 2026 19:00 HKT/SGT
|
|
|
Toys & Games Fair, Baby Products Fair and Stationery & School Supplies Fair open today
Jan 12, 2026 18:26 HKT/SGT
|
|
|
Mazda Unveils MAZDA CX-6e New Battery EV in World Premiere
Jan 12, 2026 13:10 JST
|
|
|
Argentine Football Association (AFA) teams with Verofax to offer AI Experiences to Fans 
Jan 12, 2026 10:00 HKT/SGT
|
|
|
Metaspacex Limited Partners with Popcorn Technology to Expand into Web3.0 Digital Finance
Jan 11, 2026 20:59 HKT/SGT
|
|
|
PromiCell, Inc. presents during JP Morgan's 2026 Healthcare Conference
Jan 10, 2026 07:00 HKT/SGT
|
|
|
TOYOTA GAZOO Racing Announces GR Yaris MORIZO RR
Jan 9, 2026 16:03 JST
|
|
|
Honda Announces New Lines of Models that Represent "Honda Sports DNA" at Tokyo Auto Salon 2026
Jan 9, 2026 14:24 JST
|
|
|
Honda Launches Fixed-Battery Electric Two-Wheeled Personal Commuter "Honda UC3" in Thailand and Vietnam
Jan 9, 2026 13:27 JST
|
|
|
Sponsorship Agreement Reached with LCR Honda; Full-Season MotoGP Entry as Pro Honda LCR
Jan 9, 2026 13:05 JST
|
|
|
Mazda Develops New Body Color, "Navy Blue Mica"
Jan 9, 2026 10:23 JST
|
|
|
Fujitsu develops digital learning platform for JAL to support self-directed learning and training management
Jan 9, 2026 10:07 JST
|
|
|
Capital Margin Trade Announces the Launch of Practical Trading Tools Designed For Structured Market Execution
Jan 9, 2026 07:00 HKT/SGT
|
|
|
Military Metals Announces Buyback of 1% Royalty on Slovakian Portfolio
Jan 8, 2026 20:59 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
